下一代基于抗体的癌症治疗：抗体-药物偶联物和双特异性抗体在血液系统恶性肿瘤和实体瘤中的应用

Next-generation antibody-based therapeutics in cancer: antibody-drug conjugates bispecific antibodies across hematologic malignancies and solid tumors

血液系统恶性肿瘤成人接种 SARS-CoV-2 疫苗后的抗体反应：系统综述和 meta 分析

Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis.

接受 3 剂 mRNA-1273 COVID-19 疫苗接种方案的血液系统恶性肿瘤免疫功能低下患者的抗体反应

Antibody Response in Immunocompromised Patients With Hematologic Cancers Who Received a 3-Dose mRNA-1273 Vaccination Schedule for COVID-19.

本队列研究的结果支持，对于患有血液系统恶性肿瘤的免疫功能低下患者，初次接种计划应补充延迟的第三剂疫苗接种。B 细胞淋巴瘤患者和异基因 HCT 受者需要在治疗或移植后重新接种疫苗。

血液系统恶性肿瘤成人接种 SARS-CoV-2 疫苗后的抗体反应：系统综述和 meta 分析

Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis.

使用无柱流式装置富集 CD4(+) 和 CD8(+) T 淋巴细胞用于临床细胞生产

Enrichment of CD4(+) and CD8(+) T lymphocytes with a column-free flow-based device for clinical cell manufacturing.

多剂 SARS-CoV-2 疫苗在接受 CAR-T 细胞治疗的 B 细胞血液系统恶性肿瘤患者中的疗效：一项当代队列分析

Efficacy of Multiple SARS-CoV-2 Vaccine Doses in Patients with B Cell Hematologic Malignancies Receiving Chimeric Antigen Receptor T Cell Therapy: A C

血液肿瘤双特异性单克隆抗体研究进展

Update on bi-specific monoclonal antibodies for blood cancers.

血液病患者中的 SARS-CoV-2 疫苗接种

Vaccination for SARS-CoV-2 in Hematological Patients.

SOHO 最前沿更新与后续问题：华氏巨球蛋白血症——2021 年治疗进展与未来方向

SOHO State of the Art Updates and Next Questions: Waldenström Macroglobulinemia - 2021 Update on Management and Future Directions.

复发/难治性弥漫大 B 细胞淋巴瘤的新型治疗格局

The Novel Therapeutic Landscape for Relapsed/Refractory Diffuse Large B Cell Lymphoma.